

# MARKET REPORT



Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk)

# Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

## Summary

The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. The degree and proportion of breakthrough innovations in this pipeline is exceptional – GBI Research analysis identified 333 first-in-class programs in the breast cancer pipeline, acting on 251 first-in-class molecular targets. This accounts for some 39% of all products with a disclosed molecular target, and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as despite the high attrition rate in breast cancer, it is highly likely many of the first-in-class products will reach the market over the coming decade and, will have the opportunity to transform the clinical and commercial landscape.

Potential driving factors behind this market include a very large and growing patient pool, a well-established disease market with a number of strong unmet needs, and the strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fill the unmet needs.

Some 289 first-in-class products that are currently in development have not yet been involved in licensing or co-development deals, meaning there are numerous opportunities for in-licensing or co-development in this indication, which already has a strong track record of breakthrough innovation yielding highly commercially and clinically successful therapies.

## Scope

- The report analyzes innovation in breast cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products in breast cancer, and pinpoints opportunities for in-licensing.
- A brief introduction to breast cancer, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
- The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
- Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
- Assessment of the licensing and co-development deal landscape for breast cancer therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.

## Reasons to buy

- Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
- Visualize the composition of the breast cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
- Analyze the breast cancer pipeline, stratified by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals, and producing a list of breast cancer therapies that are not yet involved in deals and may be potential investment opportunities.

## Additional Details

**Publisher :** GBI Research

**Reference :**

**Number of Pages :** 79

**Report Format :** PDF

**Publisher Information :**

The image shows a person in a lab coat and safety glasses holding a report cover. The cover features the GBI Research logo (GLOBAL BUSINESS INTELLIGENCE) and the BioPortfolio title. The background is a laboratory setting with test tubes and a person's hand in a blue glove. Overlaid on the right side of the image is promotional text for BioPortfolio, including the company name, a list of services (Life Science Healthcare and Pharmaceutical Market Research and Corporate Data), a 'Best Prices Guaranteed' guarantee, and the website URL bioportfolio.co.uk.

**GBI RESEARCH**  
GLOBAL BUSINESS INTELLIGENCE

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

# Table Of Contents for Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes [Published by GBI Research]

- 1 Table of Contents1 Table of Contents 21.1 List of Tables 31.2 List of Figures 32 Executive Summary 42.1 Exceptionally Large and Innovative Pipeline 42.2 Alignment of First-in-Class Molecular Target with Disease Causation 42.3 Highly Active Deals Landscape with Numerous Investment Opportunities 43 The Case for Innovation in the Breast Cancer Market 53.1 Growing Opportunities for Biologic Products 53.2 Diversification of Molecular Targets 53.3 Innovative First-in-Class Product Developments Remain Attractive 53.4 Changes in Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications 53.5 Sustained Innovation 63.6 Report Guidance 64 Clinical and Commercial Landscape 84.1 Disease Overview 84.2 Epidemiology 84.3 Disease Symptoms 94.4 Etiology 94.4.1 Age and Gender 94.4.2 Genetic Makeup 94.4.3 Environmental 104.5 Pathophysiology 104.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival 104.5.2 Tumor Metabolic Shift 114.5.3 Tumor Progression, Micro-environment Alteration and Angiogenesis 124.5.4 Cancer Stem Cells 134.6 Diagnosis 134.7 Prognosis and Disease Staging 144.7.1 Classification 154.8 Introduction to Breast Cancer Treatments 164.9 Surgery and Radiation Therapy 174.10 Overview of Marketed Products for Breast Cancer 174.10.1 Chemotherapy 184.10.2 Hormonal Therapies 194.10.3 Targeted Therapies 194.11 Treatment Algorithm 214.12 Current Unmet Need in Breast Cancer Market 235 Assessment of Pipeline Product Innovation 255.1 Breast Cancer Pipeline by Phase, Molecule Type and Molecular Target 255.2 First-in-Class Pipeline Programs 296 Signaling Network, Disease Causation and Innovation Alignment 366.1 The Complexity of Signaling Networks in Oncology 366.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 376.3 First-in-Class Target Matrix Assessment 377 First-in-Class Target Evaluation 417.1 Pipeline Programs which Target FGFR 3 and 4 417.2 Pipeline Programs which Target HER3 427.3 Pipeline Programs which Target PDK1 447.4 Pipeline Programs which Target Akt 1, 2 and 3 457.5 Pipeline Programs which Target PI3K-alpha 487.6 Conclusion 508 Deals and Strategic Consolidations 518.1 Industry-Wide First-in-Class Deals 518.2 Breast Cancer Deals Landscape 528.3 Licensing Deals 538.3.1 Molecule Type 558.3.2 Molecular Target 568.4 Co-development Deals 598.4.1 Molecule Type 608.4.2 Molecular Target 618.5 First-In-Class Molecules not Involved in Licensing or Co-development Deals 639 Appendix 669.1 Abbreviations 669.2 References 669.3 Contact Us 799.4 Disclaimer 79



# List Of Tables in Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes [Published by GBI Research]

## 1.1 List of Tables

Table 1: Tumor, regional lymph Node and Metastasis Staging, 2010-2013 14

Table 2: US, Disease Stage at Diagnosis and Five-year Relative Survival (%), 2013 14

Table 3: Breast Cancer Histopathological and Molecular Classification 15

Table 4: Key Features and Pipeline Activity of FGFR3 41

Table 5: Key Features and Pipeline Activity of FGFR4 42

Table 6: Pipeline Programs Targeting FGFR4 42

Table 7: Key Features and Pipeline Activity of HER3 43

Table 8: Key Features and Pipeline Activity of PDPK1 44

Table 9: Key Features and Pipeline Activity of Akt1 46

Table 10: Key Features and Pipeline Activity of Akt2 46

Table 11: Key Features and Pipeline Activity of Akt3 47

Table 12: Key Features and Pipeline Activity of PI3K-alpha 48

# List Of Figures, Charts and Diagrams in Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes [Published by GBI Research]

## 1.2 List of Figures

Figure 1: Marketed Product Overview 18

Figure 2: Treatment Algorithm for Cancer Diagnosed at Stages I to III 22

Figure 3: Treatment Algorithm for Cancer Diagnosed at Stage IV 23

Figure 4: Developmental Pipeline Overview 26

Figure 5: Developmental Pipeline Molecular Target Categories 28

Figure 6: Molecular Target Category Comparison, Pipeline and Marketed Products 29

Figure 7: Molecular Target Category Comparison, Pipeline First-in-Class and Established Molecular Targets 31

Figure 8: First-in-Class Products in the Breast Cancer Pipeline, Part 1 32

Figure 9: First-in-Class Products in the Breast Cancer Pipeline, Part 2 33

Figure 10: First-in-Class Products in the Breast Cancer Pipeline, Part 3 34

Figure 11: First-in-Class Products in the Breast Cancer Pipeline, Part 4 35

Figure 12: First-in-Class Molecular Target Analysis Matrix 38

Figure 13: First-in-Class Molecular Target Analysis Matrix 39

Figure 14: First-in-Class Molecular Target Analysis Matrix 40

Figure 15: Pipeline Programs Targeting FGFR3 42

Figure 16: Pipeline Programs Targeting HER3 43

Figure 17: Pipeline Programs Targeting PDK1 44

Figure 18: Pipeline Programs Targeting Akt1 47

Figure 19: Pipeline Programs Targeting Akt2 47

Figure 20: Pipeline Programs Targeting Akt3 48

Figure 21: Pipeline Programs Targeting PI3K 49

Figure 22: Industry-Wide Deals by Stage of Development, 2006-2014 51

Figure 23: Industry Licensing Deal Values by Stage of Development (\$m), 2006-2014 52

Figure 24: Global, Licensing Deals by Region and Value, 2006-2014 54

Figure 25: Global, Licensing Deals by Stage and Value, 2006-2014 55

Figure 26: Licensing Deals by Molecule Type, 2006–2014	56
Figure 27: Licensing Deals by Molecular Target, 2006–2014	56
Figure 28: Licensing Deals, 2006–2014	57
Figure 29: Licensing Deals, 2006–2014	58
Figure 30: Co-Development Deals, 2006–2014	59
Figure 31: Co-Development Deals, 2006–2014	60
Figure 32: Co-Development Deals by Molecule Type, 2006–2014	61
Figure 33: Co-Development Deals by Molecular Target, 2006–2014	61
Figure 34: Co-Development Deals, 2006–2014	62
Figure 35: First-in-Class Programs with no Prior Deal Involvement, Part 1	63
Figure 36: First-in-Class Programs with no Prior Deal Involvement, Part 2	64
Figure 37: First-in-Class Programs with no Prior Deal Involvement, Part 3	65



# How to Buy...

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes [Published by GBI Research]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/25765>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$6995** | Single User Price
- \$13990** | Site License Price
- \$20985** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.